Gut microbiota-mediated personalized treatment for hyperlipidemia using berberine

Yan Wang¹*,#, Qian Tong²#, Jia-Wen Shou¹#, Zhen-Xiong Zhao¹, Xiao-Yang Li¹,
Xian-Feng Zhang², Shu-Rong Ma¹, Chi-Yu He¹, Yuan Lin¹, Bao-Ying Wen¹, Fang Guo¹,
Jie Fu¹, Jian-Dong Jiang¹*

¹ State Key Laboratory of Bioactive Substance and Function of Natural Medicines,
Institute of Materia Medica, Chinese Academy of Medical Sciences / Peking Union
Medical College, Beijing 100050, China; ² The First Hospital of Jilin University,
Changchun, 130021

# These authors made an equal contribution to this work.

* Corresponding author: Dr. Yan Wang, Tel.: +86 10 63165238; fax, +86 10 63165238.
E-mail address: wangyan@imm.ac.cn; or Dr. Jian-Dong Jiang, Tel.: +86 10 83160005;
fax, +86 10 63017757. E-mail address: jiang.jdong@163.com.
Supplementary information

Figure legends

Supplementary Figure 1: Chemical structure of BBR and its main metabolites.

Supplementary Figure 2: Concentration of BBR main metabolites, M1-M5, in the small intestines of the HFD-fed or ND-fed hamsters ($P<0.05$; n=5 for the ND-fed and n=6 for the HFD-fed hamsters).

Supplementary Figure 3: Concentration of BBR main metabolites M1-M5 in the livers of HFD-fed or ND-fed hamsters ($P<0.05$; n=5 for the ND-fed hamsters, and n=6 for the HFD-fed hamsters).

Supplementary Figure 4: Blood concentration of BBR in human subjects. No difference was observed in plasma BBR concentrations between male and female and between those above 50 and below 50 years old ($NS$: no significance).